Bethfaiman Profile Banner
Beth Faiman PhD Profile
Beth Faiman PhD

@Bethfaiman

Followers
1K
Following
10K
Media
248
Statuses
4K

Passionate about the diagnosis, management & care of patients with #multiplemyeloma #amyloidosis and #bloodcancer. And my family❤️. Tweets are my own.

Cleveland Ohio
Joined May 2014
Don't wanna be here? Send us removal request.
@VincentRK
Vincent Rajkumar
20 hours
One of the main goals of our review article in @NEJM on MGUS was to provide clear clarifications on the concept of “monoclonal gammopathy of clinical significance” (MGCS). It’s all very confusing in the literature and can cause problems for patients if we are not totally clear of
Tweet card summary image
nejm.org
MGUS is a common, asymptomatic plasma-cell disorder in older adults that can progress to cancer or systemic illness. Diagnosis warrants follow-up, but treatment is not required unless progression i...
5
52
180
@Amyloidosis_ASB
Amyloidosis Speakers Bureau
2 days
Amazing day at @AmyloidosisSupp bi-annual ATTR conference! Massive turnout of over 500, and the largest ever group of amyloidologists! Patients found the day amazing, filled with a ton of valuable information! Congrats Muriel and team!
0
1
7
@RahulBanerjeeMD
Rahul Banerjee, MD, FACP
2 days
@AmandaNizamMD @neerajaiims @montypal @OncBrothers @NazliDizman @AnaVManana @MinhTriMD @jamecancerdoc @brian_rini This is an excellent summary! Fascinating that with different target but same payload, brentuximab vedotin in lymphoma is much more known for neuropathy but not so much for the others. Evidently, both the target and the payload matter for ADCs!!
1
1
8
@Thatquaratined1
#MultipleMyelomaAwareness
2 days
Expanded capacity for telehealth use and increased competency in providing remote care has been one of the few good impacts the pandemic had on healthcare globally. We need to build on this and further enable access to telemedicine, not limit it!
@RahulBanerjeeMD
Rahul Banerjee, MD, FACP
3 days
For someone who normally writes everything with an enthusiastic tone, this was hard but important to write. Lost amidst the DC chaos is the expiration of the Medicare telehealth waiver and its effects on many of my patients living with cancers such as myeloma. Please fix ASAP!
0
2
5
@Myeloma_Doc
Robert Z. Orlowski
1 day
#Myeloma Paper of the Day: Important overview of 35 years of academic trials focusing on high-dose therapy and autologous stem cell transplantation from the Intergroupe Francophone du Myélome (IFM) experience: https://t.co/5hW5TF4aog. #mmsm
1
6
29
@DrOlaLandgren
C. Ola Landgren, M.D.
2 days
Thank you very much Florida Society of Clinical Oncology (FLASCO) for inviting me to give a talk on “clinical applications for MRD testing in multiple myeloma” at the FLASCO Fall Congress, October 23-25, 2025 in Orlando! #mmsm @theMMRF @IMFmyeloma @SylvesterCancer
2
2
9
@Bethfaiman
Beth Faiman PhD
22 hours
Well said! #Telehealth #myeloma #mmsm @RahulBanerjeeMD this👇 is so true!
@Thatquaratined1
#MultipleMyelomaAwareness
2 days
@RahulBanerjeeMD @sghmd I could NOT imagine navigating a chronic cancer w comorbidities without access to telemedicine. It would significantly impact not just our ability to get timely interventions and the overall quality of care but would eat into our capacity to find balance and quality of life.
0
1
4
@Bethfaiman
Beth Faiman PhD
2 days
What a great day, and a great campaign to raise awareness of the #APP role in #oncology! #MakeItHAPPen #APSHO #JnJOncology #APPs #JADPROLive25
@victoriawongpac
Victoria Wong
2 days
Honored to have been invited to share the stage with these wonderful minds discussing APP impact in cancer care at JADPRO Live 2025! @Bethfaiman #MakeItHAPPen #APSHO #JnJOncology #APPs #JADPROLive
0
1
2
@Bethfaiman
Beth Faiman PhD
2 days
Thank you for writing @RahulBanerjeeMD!! Interactions via #telehealth have been critical to my practice and monitoring for side effects, response. Some ppl can’t get a ride, lack time to travel. We need to use our collective voices to bring awareness! #mmsm #myeloma #medicare
@RahulBanerjeeMD
Rahul Banerjee, MD, FACP
3 days
For someone who normally writes everything with an enthusiastic tone, this was hard but important to write. Lost amidst the DC chaos is the expiration of the Medicare telehealth waiver and its effects on many of my patients living with cancers such as myeloma. Please fix ASAP!
2
1
4
@hhashmi87
Hamza Hashmi
4 days
I remember this post and patient story from 4 years ago. Therapeutic advances in #MMSM need to be offered to those most in need of them. BelaVd would be a great option for many pts who are unable to receive BsAb and CAR T. #MMSM #MedTwitter #CureMyeloma #UnMetNeed #MedEd
@hhashmi87
Hamza Hashmi
4 years
Myeloma Story: My old & frail pt w RRMM, 6 prior lines of Rx, renal failure on hemodialysis, drove 3.5 hrs to receive 1 dose of BlenRep and it absorbed the light chains like a 'sponge'. Fascinated what Immunotherapy (ADC/BITE/CAR T) can do these days (no COI) #MMSM #CureMyeloma
0
4
16
@AprilKapu
April Kapu, DNP, ACNP-BC
3 days
Fantastic session on APP onboarding at the ⁦@VUMChealth#APP Retreat today by ⁦@JacksonHeatherJ⁩ ! ⭐️Also looking forward to Dr. Jackson’s pain management sessions at the first ever https://t.co/nfPadMPvJ9 conference Nov. 7-9!
1
1
2
@Mohty_EBMT
Mohamad Mohty
4 days
Honored to have led this long-term follow-up analysis of the REACH2 trial, a landmark study that paved the way for the 1st approved treatment in steroid-refractory aGVHD. Deeply grateful to all investigators, study teams, and stakeholders whose dedication made this achievement
@JCO_ASCO
Journal of Clinical Oncology
4 days
Ruxolitinib Versus Best Available Therapy in Patients With Steroid-Refractory Acute Graft-Versus-Host Disease: Final Analysis From the Randomized Phase III REACH2 Trial. Co-authored by @Mohty_EBMT. Read the full article.
1
9
37
@hhashmi87
Hamza Hashmi
3 days
With median fu of 17m, no cases of cerebellar toxicity seen in 18 pts. No major Skin/Oral/Nail toxicities. Efficacy data appears similar to Arlo-cel. N is small but is finding the ✅ dose the trick for avoiding 🧠toxicities for GPRC5d CAR T #MMSM #Myeloma
@Myeloma_Doc
Robert Z. Orlowski
3 days
#Myeloma Paper of the Day: CAR T w/ fully human single-domain antibody fragment targeting GPRC5D shows ORR 94.4% (72.2% CR/sCR) & 85.7% if prior BCMA CAR T-cell therapy; median PFS 18.2 months; CRS in 88.9% (primarily grade 1-2); 1 grade 3 ICANS: https://t.co/R5H0XNbzsj. #mmsm
0
1
8
@DrGarethMorgan1
Gareth Morgan
3 days
Good job Lou
@LouisWilliamsMD
Louis Williams
3 days
Happy to share our experience in managing #MGRS in @BrJHaem. #PGNMID remains an area for improvement. Excellent work by Daniel Cancilla and our coauthors. @Bethfaiman @FaizAnwerMD1 @khouri_jack @jamecancerdoc @CleClinicMD #mmsm https://t.co/N57ht8Nt2t
1
1
7
@Bethfaiman
Beth Faiman PhD
3 days
Such an HONOR to speak with you on the topic of #myeloma! Your presentation style and presence is unparalleled, Josh!! 👏👏let’s take this show on the road! Thanks for speaking for us #JADPROLive25 @APSHOorg
@JoshuaRichterMD
Joshua Richter, MD, FACP
3 days
Excited to be at #JADPROLive25 with ⁦@Bethfaiman⁩ talking about myeloma. #mmsm
0
2
13
@DrGarethMorgan1
Gareth Morgan
4 days
Caught in the act of public speaking thx for the opportunity and to the organisers
@VJHemOnc
VJHemOnc
4 days
Kicking off session 3 at #iwHRMM25 with @DrGarethMorgan1 of @nyulangone, who is discussing the transcriptional drivers of aggressive clinical behavior. 🩸🎤 #MMSM #MultipleMyeloma #Myeloma #HemOnc
0
2
11
@IMFmyeloma
International Myeloma Foundation
4 days
Today, the U.S. FDA has approved Blenrep (with bortezomib + dexamethasone) for adults with relapsed/refractory multiple myeloma after 2+ prior treatments. ​​Read now: https://t.co/v1EKvtMbo4 #mmsm #myeloma
0
5
10
@IMFsupport
Robin Tuohy
4 days
“Put a period on the end of your sentence when making an ask”. I am at #HealtheMatters an initiative of ⁦@MyelomaCanada⁩. Moving the Conversation Dylan Buskermolen #HeMFall25
0
1
3
@RahulBanerjeeMD
Rahul Banerjee, MD, FACP
3 days
At Seattle #MMsm rounds: very nice presentation by @DimaDanai walking through her approach to EMD. She emphasizes that ‘holding’ therapy before T cell collection is super important for EMD in RRMM: don’t assume disease will stay still for 3 weeks while you collect for CAR-T!
0
9
29